umbralisib (Ukoniq)

From Aaushi
Jump to navigation Jump to search

Indications

* FDA has withdrawn approval for Ukoniq (umbralisib) due to safety concerns[2]

* manufacturer, TG Therapeutics announced it ws voluntarily withdrawing Ukoniq from the market

Dosage

200 mg tablets

Adverse effects

Mechanism of action

More general terms

References

  1. FDA Drug Approval. Feb 5, 2021 FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-umbralisib-marginal-zone-lymphoma-and-follicular-lymphoma
  2. 2.0 2.1 2.2 Stern V FDA Withdraws Lymphoma Drug Approval After Investigation. Medscape. June 1, 2022 https://www.medscape.com/viewarticle/974875
    FDA Drug Safety Communication. 2022. June 1. FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns. Possible increased risk of death outweighs the benefits. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approval-lymphoma-medicine-ukoniq-umbralisib-withdrawn-due-safety-concerns

Database